Browse 285 glioblastoma clinical trials enrolling across the United States and Canada. Search by city or state to find one near you.
Filter
1
Filter results
Results: 285
B7-H3 Chimeric Antigen Receptor T Cells (B7-H3CART) in Recurrent Glioblastoma Multiforme
for
Brain and Nervous System
Location: Palo Alto CA
Sponsor: Stanford University
Sex: All
Age: 18+
Code: NCT05474378
Phase1, Recruiting
Spectroscopic MRI, Proton Therapy, and Avastin for Recurrent Glioblastoma
for
Recurrent Glioblastoma
Location: Miami FL
Sponsor: University of Miami
Sex: All
Age: 18+
Code: NCT05284643
Recruiting
Treatment of Relapsed/Refractory Intracranial Glioma in Patients Under 22 Years of Age
for
Glioblastoma Multiforme, Anaplastic Astrocytoma,
Location: Miami FL
Sponsor: University of Miami
Sex: All
Age: 1 - 21
Code: NCT05956821
Phase1, Phase2, Recruiting
Biologic Association Between Metabolic Magnetic Resonance-positron Emission Tomograph (MR-PET) and Tissue Measures of Glycolysis in Brain Tumors of Infiltrating Glioblastoma Cells
for
Glioblastoma Multiforme, Glycolytic Index,
Location: Los Angeles CA
Sponsor: Jonsson Comprehensive Cancer Center
Sex: All
Age: 18+
Code: NCT06059690
Phase1, Phase2, Recruiting
Autologous CAR-T Cells Targeting B7-H3 in Recurrent or Refractory GBM CAR.B7-H3Tc
for
Glioblastoma Multiforme
Location: Chapel Hill NC
Sponsor: UNC Lineberger Comprehensive Cancer Center
Sex: All
Age: 18+
Code: NCT05366179
Phase1, Recruiting
Interested in new trials?
Get alerts for new trials in your area by subscribing now
BGB-58067 in Newly Diagnosed Glioblastoma Patients With MTAP-Deleted Tumors
for
Glioblastoma (GBM)
Location: Phoenix AZ
Sponsor: Nader Sanai
Sex: All
Age: 18+
Code: NCT07485049
Early_phase1, Recruiting
A Phase 0/1 Clinical Trial With an Expansion Phase of GSK5764227, a B7-H3-Targeted Antibody-Drug Conjugate (ADC), in Patients With Recurrent Grade 4 Glioma and Patients With Brain Metastases
for
Glioblastoma (GBM), Brain Metastasases
Location: Phoenix AZ
Sponsor: Nader Sanai
Sex: All
Age: 18+
Code: NCT07268053
Early_phase1, Recruiting
Imaging Acetadote Metabolism in Glioblastoma
for
Glioblastoma, GBM
Location: Dallas TX
Sponsor: University of Texas Southwestern Medical Center
Sex: All
Age: 18+
Code: NCT07387666
Early_phase1, Recruiting
ERAS-801 for the Treatment of Resectable and Progressive or Recurrent or Elderly Newly Diagnosed IDH Wildtype Grade IV Glioblastoma or Gliosarcoma With an EGFR Amplification or Mutation, ERAS801-SARG Trial
Radiotherapy Planning Using Fluciclovine PET in Patients With Newly Diagnosed Glioblastoma
for
Newly Diagnosed Glioblastoma
Location: Phoenix AZ
Sponsor: St. Joseph's Hospital and Medical Center, Phoenix
Sex: All
Age: 18+
Code: NCT04840069
Phase2, Recruiting
Investigation Into the Differentiation of Tumour and Healthy Brain Tissue Using Multi-exponential T2 Components
for
Glioma
Location: Edmonton
Sponsor: AHS Cancer Control Alberta
Sex: All
Age: 18+
Code: NCT00813787
Recruiting
Dabrafenib and/or Trametinib Rollover Study
for
Melanoma, Non Small Cell Lung Cancer, Solid Tumor, Rare Cancers,
Location: Toronto
Sponsor: Novartis Pharmaceuticals
Sex: All
Age: 18 - 70+
Code: NCT03340506
Recruiting
International Diffuse Intrinsic Pontine Glioma (DIPG)/Diffuse Midline Glioma (DMG) Registry and Repository
for
Diffuse Intrinsic Pontine Glioma,
Location: Cincinnati OH
Sponsor: Children's Hospital Medical Center, Cincinnati
Sex: All
Age: 0+
Code: NCT03101813
Recruiting
Panitumumab-IRDye800 in Diagnosing Participants With Malignant Glioma Undergoing Surgery
for
Malignant Brain Neoplasm, Malignant Glioma
Location: Palo Alto CA
Sponsor: Stanford University
Sex: All
Age: 18+
Code: NCT03510208
Phase1, Phase2, Recruiting
Zr-89 Crefmirlimab Berdoxam and Immuno-Positron Emission Tomography for the Imaging of Patients With Resectable Brain Tumors
for
Glioma, Malignant Brain Neoplasm, Meningioma,
Location: Los Angeles CA
Sponsor: Jonsson Comprehensive Cancer Center
Sex: All
Age: 18+
Code: NCT06650163
Phase1, Recruiting
Magnetic Resonance (MR) Imaging to Determine High Risk Areas in Patients With Malignant Gliomas and to Design Potential Radiation Plans and to Examine Metabolite Changes in Gliomas and Other Solid Tumors